Format

Send to

Choose Destination
J Med Chem. 2010 Nov 25;53(22):8187-91. doi: 10.1021/jm1006148. Epub 2010 Oct 27.

Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation.

Author information

1
Biosciences Division, SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025, USA. nurulain@astraeatherapeutics.com

Abstract

Antagonist activity at the α3β4 nicotinic acetylcholine receptor (nAChR) is thought to contribute to the antiaddictive properties of several compounds. However, truly selective ligands for the α3β4 nAChR have not been available. We report the discovery and SAR of a novel class of compounds that bind to the α3β4 nAChR and have no measurable affinity for the α4β2 or α7 subtype. In functional assays the lead compound antagonized epibatidine-induced Ca(2+) flux in α3β4-transfected cells in a noncompetitive manner.

PMID:
20979364
PMCID:
PMC2997436
DOI:
10.1021/jm1006148
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center